Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | HK2 | P52789 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31174385 | 1.00 | ESR2 (0.47) | ESR2KDM4EALDH1A1ESR1ADORA3 | |
| Hydrochloric Acid SCHEMBL2442635 | 0.98 | KDM4E (0.49) | ESR2KDM4EALDH1A1ESR1ADORA3 | |
| SCHEMBL15307765 | 0.77 | MAOB (0.47) | ESR2KDM4EALDH1A1ESR1ADORA3 | |
| SCHEMBL633722 | 0.73 | ESR2 (0.40) | ESR2KDM4EALDH1A1ESR1ADORA3 | |
| SCHEMBL35864 | 0.72 | HSPA5 (0.43) | CYP3A4CYP2C9MEN1LMNAMAPT | |
| SCHEMBL29368767 | 0.72 | HSPA5 (0.43) | CYP3A4CYP2C9MEN1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL3572840 | 0.71 | KDM4E (0.41) | ESR2KDM4EALDH1A1ESR1ADORA3 | |
| SCHEMBL23067398 | 0.71 | AOC2 (0.41) | ESR2KDM4EALDH1A1ESR1ADORA3 | |
| SCHEMBL28475321 | 0.71 | SELL (0.45) | — | |
| SCHEMBL5458032 | 0.71 | TYR (0.58) | KDM4EALDH1A1CYP3A4MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| CN-118858482-A | Method for simultaneously detecting blood concentration of levodopa, benserazide and 2,3, 4-trihydroxybenzylhydrazine | 天津汉一医药科技有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-117142978-A | Preparation method of benserazide hydrochloride and application of benserazide hydrochloride in composition | 重庆圣华曦药业股份有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-116271044-A | Application of inhibiting cystathionine beta synthase in immunotherapy | 同济大学 | 2023-06-23 | — | — | CN | claimed |
| US-20210220298-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING METABOLIC SYNDROME INDUCED BY ANTIPSYCHOTIC TREATMENT AND RELATED DISEASES AND CONDITIONS | TUFTS MEDICAL CENTER, INC. | 2021-07-22 | — | — | US | claimed |
| EP-3101001-B1 | DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | TEVA PHARMACEUTICALS INT GMBH (CH) | 2020-04-01 | — | — | EP | claimed |
| US-20070082953-A1 | Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases | BDD BEROLINA DRUG DEVELOPMENT GMBH (DE) | 2007-04-12 | — | — | US | claimed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| US-4424235-A | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor | HOFFMANN-LA ROCHE INC. (US) | 1984-01-03 | — | — | US | claimed |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| CN-117142978-B | Preparation method of benserazide hydrochloride and application of benserazide hydrochloride in composition | 重庆圣华曦药业股份有限公司 | 2025-11-04 | — | — | CN | disclosed |
| CN-118858482-A | Method for simultaneously detecting blood concentration of levodopa, benserazide and 2,3, 4-trihydroxybenzylhydrazine | 天津汉一医药科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | disclosed |
| US-4849408-A | GLYCYLTRYPTOPHAN, ANTIDEPRESSANTS, SEDATIVES | (501) FRESENIUS AG (DE) | 1989-07-18 | — | — | US | disclosed |
| WO-1989001774-A1 | PHARMACEUTICAL COMPOSITIONS | SAAD AL DAMLUJI (GB) | 1989-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | GPR119, TPH1, LIPC | ESR2 2873/4885KDM4E 1845/4885ALDH1A1 971/4885 |
| US-20210220298-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING METABOLIC SYNDROME INDUCED BY ANTIPSYCHOTIC TREATMENT AND RELATED DISEASES AND CONDITIONS | GPR119, PC, NLN | ESR2 2152/4885KDM4E 3272/4885ALDH1A1 1625/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | ESR2 4555/4885KDM4E 1203/4885ALDH1A1 100/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | ESR2 4614/4885KDM4E 935/4885ALDH1A1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.